Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

Amar Gajjar,Giles W. Robinson,Kyle S Smith,Tong Lin,Thomas E. Merchant,Murali Chintagumpala,Anita Mahajan,Jack Su,Eric Bouffet,Ute Bartels,Tal Schechter,Tim Hassall,Thomas Robertson,Wayne Nicholls,Sridharan Gururangan,Kristin Schroeder,Michael J. Sullivan,Greg Wheeler,Jordan R. Hansford,Stewart J. Kellie,Geoffrey McCowage,Richard J. Cohn,Michael Fisher,Matthew J. Krasin,Clinton F. Stewart,Alberto Broniscer,Ivo Buchhalter,Ruth G. Tatevossian,Brent A. Orr,Geoff Neale,Paul Klimo,Frederick A. Boop,Ashok Srinivasan,Stefan M. Pfister,Richard J. Gilbertson,Arzu Onar-Thomas,David W. Ellison,Paul A. Northcott

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)

2021

PURPOSESJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alte...

Keywords:

Clinical significance
Medulloblastoma
Internal medicine
Medicine
Oncology
MEDLINE

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations